Literature DB >> 35387855

Effectiveness of a Self-Management Program to Improve Cognition and Quality of Life in Epilepsy: A Pragmatic, Randomized, Multicenter Trial.

Nicholas A Streltzov1, Samantha S Schmidt1, Lindsay M Schommer1, Wenyan Zhao1, Tor D Tosteson1, Morgan T Mazanec1, Elaine T Kiriakopoulos1, Felicia Chu1, Heidi L Henninger1, Keith Nagle1, Robert M Roth1, Barbara Jobst1.   

Abstract

BACKGROUND AND OBJECTIVES: We conducted a multisite, pragmatic replication trial at 4 New England epilepsy centers to determine the effectiveness of Home-Based Self-Management and Cognitive Training Changes Lives (HOBSCOTCH) in a real-world setting and to assess feasibility of a virtual intervention.
METHODS: HOBSCOTCH is an 8-session intervention addressing cognitive impairment and quality of life (QoL) for people with epilepsy (PWE). Participants were recruited from epilepsy centers in 4 states and block-randomized into the following groups: in-person HOBSCOTCH (H-IP), virtual HOBSCOTCH (H-V), and waitlist control. Outcome measures were assessed for all groups at baseline, 3 months, and 6 months; intervention groups received long-term follow-up at 9 and 12 months.
RESULTS: A total of 108 participants were recruited, of whom 85 were included in this analysis (age at baseline 47.5 ± 11.5 years; 68% female). Participants completing the in-person intervention (H-IP) had a 12.4-point improvement in QoL score compared with controls (p < 0.001). Pairwise comparisons found a 6.2-point treatment effect for subjective cognition in the H-IP group (p < 0.001). There were no meaningful group differences in objective cognition or health care utilization at any time points and the treatment effect for QoL diminished by 6 months. The virtual intervention demonstrated feasibility but did not significantly improve outcomes compared with controls. Within-group analysis found improvements in QoL for both H-V and H-IP. DISCUSSION: This study replicated the effectiveness of the HOBSCOTCH program in improving QoL for PWE. The study was conducted prior to the COVID-19 pandemic, but the distance-delivered intervention may be particularly well-suited for the current environment. Future research will explore modifications designed to improve the efficacy of H-V and the sustainability of HOBSCOTCH's treatment effect. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov (NCT02394509). CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in-person HOBSCOTCH delivery improved subjective measures of cognition in persons with epilepsy.
© 2022 American Academy of Neurology.

Entities:  

Mesh:

Year:  2022        PMID: 35387855      PMCID: PMC9169940          DOI: 10.1212/WNL.0000000000200346

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   11.800


  46 in total

1.  Pragmatic clinical trials.

Authors:  Hugh Macpherson
Journal:  Complement Ther Med       Date:  2004 Jun-Sep       Impact factor: 2.446

2.  Pragmatic trials--guides to better patient care?

Authors:  James H Ware; Mary Beth Hamel
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

3.  Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures.

Authors:  Simon Borghs; Christine de la Loge; Joyce A Cramer
Journal:  Epilepsy Behav       Date:  2012-02-15       Impact factor: 2.937

4.  The cost of epilepsy in the United States: an estimate from population-based clinical and survey data.

Authors:  C E Begley; M Famulari; J F Annegers; D R Lairson; T F Reynolds; S Coan; S Dubinsky; M E Newmark; C Leibson; E L So; W A Rocca
Journal:  Epilepsia       Date:  2000-03       Impact factor: 5.864

Review 5.  Memory dysfunction in epilepsy patients as a derangement of normal physiology.

Authors:  E Halgren; J Stapleton; P Domalski; B E Swartz; A V Delgado-Escueta; G O Walsh; M Mandelkern; W Blahd; J Ropchan
Journal:  Adv Neurol       Date:  1991

6.  Attrition in Chronic Disease Self-Management Programs and self-efficacy at enrollment.

Authors:  Nina Verevkina; Yunfeng Shi; Veronica Alejandra Fuentes-Caceres; Dennis Patrick Scanlon
Journal:  Health Educ Behav       Date:  2014-04-25

7.  Depressive, inflammatory, and metabolic factors associated with cognitive impairment in patients with epilepsy.

Authors:  Josi Arend; Aline Kegler; Ana Letícia Fornari Caprara; Camila Almeida; Patricia Gabbi; Eduardo T Pascotini; Lori Ane Vargas de Freitas; Cinara Miraglia; Taíse Leitemperger Bertazzo; Raphael Palma; Patrícia Arceno; Marta M M F Duarte; Ana Flavia Furian; Mauro Schneider Oliveira; Luiz Fernando Freire Royes; Gary W Mathern; Michele Rechia Fighera
Journal:  Epilepsy Behav       Date:  2018-08-02       Impact factor: 2.937

8.  Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy.

Authors:  David Victorson; Jose E Cavazos; Gregory L Holmes; Anthony T Reder; Valerie Wojna; Cindy Nowinski; Deborah Miller; Sarah Buono; Allison Mueller; Claudia Moy; David Cella
Journal:  Epilepsy Behav       Date:  2013-12-20       Impact factor: 2.937

Review 9.  Epilepsy and neuropsychological comorbidities.

Authors:  Leslie A Rudzinski; Kimford J Meador
Journal:  Continuum (Minneap Minn)       Date:  2013-06

10.  The effect of COVID-19 pandemic on seizure control and self-reported stress on patient with epilepsy.

Authors:  Amal Alkhotani; Muhammad I Siddiqui; Fahad Almuntashri; Renad Baothman
Journal:  Epilepsy Behav       Date:  2020-07-14       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.